Symmetrical pattern
Biosimilar logo
Biosimilars
Biosimilars

Biosimilars

Providing Affordable,
Accessible Care
for Patients

Biologics represent the fastest growing class of medicines in the United States. They also account for an increasingly large portion of healthcare costs.1

Sandoz is committed to helping patients with neurological conditions access affordable, quality care through the use of biosimilars.

Reviewed through a rigorous FDA approval process

Reviewed through a rigorous FDA approval process

Biosimilars are biologics, a type of medicine produced from living sources that are used to safely and effectively treat many illnesses.2 Biosimilars are reviewed through a rigorous Food and Drug Administration (FDA) approval process, just like biologics.2

Biosimilars are approved based on the totality of evidence demonstrating3:
They are highly similar to an FDA-approved biologic, known as the reference biologic
There are no clinically meaningful differences in safety, purity, and potency
Learn more about biosimilars
Reviewed through a rigorous FDA approval process

Addressing the rising costs of managing neurological conditions

Out-of-pocket costs for medications to treat neurological conditions, such as multiple sclerosis, peripheral neuropathy, epilepsy, dementia, and Parkinson’s disease, have increased sharply over 12 years.5

In the future, biosimilars may help patients gain improved access to a quality, cost-effective, FDA-approved medicine without compromising safety and efficacy.3

Explore benefits for patients and neurologists
Addressing the rising costs of managing neurological conditions

$500B+

Annual cost of treating neurologic disorders in the United States4

Photos used are not of actual patients or healthcare professionals.
References
  1. U.S. Food & Drug Administration. Biosimilar Regulatory Review and Approval. https://www.fda.gov/media/151061/download#:~:text=Biosimilar%20Approval%20Process&text=FDA%20assesses%20a%20manufacturer's%20strategy%20to%20control%20the%20extent%20of,all%20medications%20after%20their%20approval. Accessed July 3, 2022.
  2. U.S. Food & Drug Administration. Overview of
    Biosimilar Products. https://www.fda.gov/media/151058/downloadAccessed July 3, 2022.
  3. U.S. Food & Drug Administration. Biosimilar Product Regulatory Review and Approval. https://www.fda.gov/media/108621/download. Accessed April 8, 2022.
  4. American Academy of Neurology. Out‑of‑pocket‑costs for neurologic medications rise sharply over 12 years. https://www.aan.com/PressRoom/Home/PressRelease/2717. Accessed August 2, 2022.
  5. Callaghan B, Reynolds E, Banerjee M, et al. Out-of-pocket costs are on the rise for commonly prescribed neurologic medications. Neurology. 2019:92;e2604‑e2613.